204 related articles for article (PubMed ID: 9535177)
1. Perspectives in antisense therapeutics.
Agrawal S; Iyer RP
Pharmacol Ther; 1997; 76(1-3):151-60. PubMed ID: 9535177
[TBL] [Abstract][Full Text] [Related]
2. Antisense treatments for biothreat agents.
Warfield KL; Panchal RG; Aman MJ; Bavari S
Curr Opin Mol Ther; 2006 Apr; 8(2):93-103. PubMed ID: 16610760
[TBL] [Abstract][Full Text] [Related]
3. Sugar boost: when ribose modifications improve oligonucleotide performance.
Faria M; Ulrich H
Curr Opin Mol Ther; 2008 Apr; 10(2):168-75. PubMed ID: 18386229
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of oligonucleotides.
Agrawal S; Zhang R
Ciba Found Symp; 1997; 209():60-75; discussion 75-8. PubMed ID: 9383569
[TBL] [Abstract][Full Text] [Related]
5. 2'-Modified oligonucleotides for antisense therapeutics.
Prakash TP; Bhat B
Curr Top Med Chem; 2007; 7(7):641-9. PubMed ID: 17430205
[TBL] [Abstract][Full Text] [Related]
6. In vitro toxicology and pharmacokinetics of antisense oligonucleotides.
Crooke RM
Anticancer Drug Des; 1991 Dec; 6(6):609-46. PubMed ID: 1772572
[TBL] [Abstract][Full Text] [Related]
7. Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides.
Agrawal S
Biochim Biophys Acta; 1999 Dec; 1489(1):53-68. PubMed ID: 10806997
[TBL] [Abstract][Full Text] [Related]
8. Antisense oligonucleotide pharmacokinetics and metabolism.
Geary RS
Expert Opin Drug Metab Toxicol; 2009 Apr; 5(4):381-91. PubMed ID: 19379126
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B1 and CDC 2 kinase) in the vessel wall in vivo: enhanced therapeutic utility for restenosis by HVJ-liposome delivery.
Morishita R; Gibbons GH; Kaneda Y; Ogihara T; Dzau VJ
Gene; 1994 Nov; 149(1):13-9. PubMed ID: 7958977
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides.
Geary RS; Norris D; Yu R; Bennett CF
Adv Drug Deliv Rev; 2015 Jun; 87():46-51. PubMed ID: 25666165
[TBL] [Abstract][Full Text] [Related]
11. Antisense and/or immunostimulatory oligonucleotide therapeutics.
Agrawal S; Kandimalla ER
Curr Cancer Drug Targets; 2001 Nov; 1(3):197-209. PubMed ID: 12188879
[TBL] [Abstract][Full Text] [Related]
12. Antisense oligonucleotides as therapeutic agents--is the bullet really magical?
Stein CA; Cheng YC
Science; 1993 Aug; 261(5124):1004-12. PubMed ID: 8351515
[TBL] [Abstract][Full Text] [Related]
13. Antisense strategy: biological utility and prospects in the treatment of hematological malignancies.
Warzocha K; Wotowiec D
Leuk Lymphoma; 1997 Jan; 24(3-4):267-81. PubMed ID: 9156656
[TBL] [Abstract][Full Text] [Related]
14. Progress in the delivery of therapeutic oligonucleotides: organ/cellular distribution and targeted delivery of oligonucleotides in vivo.
Wang L; Prakash RK; Stein CA; Koehn RK; Ruffner DE
Antisense Nucleic Acid Drug Dev; 2003; 13(3):169-89. PubMed ID: 12954117
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of therapeutic oligonucleotides.
Diasio RB; Zhang R
Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):239-43. PubMed ID: 9212918
[No Abstract] [Full Text] [Related]
16. Rational design and rapid screening of antisense oligonucleotides for prokaryotic gene modulation.
Shao Y; Wu Y; Chan CY; McDonough K; Ding Y
Nucleic Acids Res; 2006; 34(19):5660-9. PubMed ID: 17038332
[TBL] [Abstract][Full Text] [Related]
17. An overview of sugar-modified oligonucleotides for antisense therapeutics.
Prakash TP
Chem Biodivers; 2011 Sep; 8(9):1616-41. PubMed ID: 21922654
[TBL] [Abstract][Full Text] [Related]
18. Influence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotides.
Dirin M; Winkler J
Expert Opin Biol Ther; 2013 Jun; 13(6):875-88. PubMed ID: 23451977
[TBL] [Abstract][Full Text] [Related]
19. Antisense oligonucleotides: towards clinical trials.
Agrawal S
Trends Biotechnol; 1996 Oct; 14(10):376-87. PubMed ID: 8987636
[TBL] [Abstract][Full Text] [Related]
20. Antisense oligonucleotides as therapeutics for malignant diseases.
Ho PT; Parkinson DR
Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
